Patients with severe chronic kidney disease or end stage renal disease (ESRD) on hemodialysis
(HD) exhibited higher platelet reactivity to clopidogrel than did those with normal renal
function. Not enough study has been conducted about the antiplatelet effects of ticagrelor in
these cardiovascular high risk patients. We hypothesized ticagrelor would achieve more and
faster antiplatelet effects compared with clopidogrel in ESRD patients on HD.